[Factors associated with mortality due to SARS-CoV-2 in the population over 75 years of age in the Community of Madrid] [0.03%]
马德里地区75岁以上人群感染SARS-CoV-2死亡率的相关因素分析
J M Mostaza,M A Salinero-Fort,J Cardenas-Valladolid et al.
J M Mostaza et al.
Objective: Various studies have identified factors associated with risk of mortality in patients with SARS-CoV-2 infection. However, their sample size has often been limited and their results partially contradictory. This...
[Nosocomial outbreak of COVID-19 in an internal medicine ward: Probable airborne transmission] [0.03%]
[一起内科病房新冠肺炎医院感染事件：疑似气溶胶传播]
M Andrés,M-C García,A Fajardo et al.
M Andrés et al.
Background and objectives: Despite the increasing evidence supporting the importance of airborne transmission in SARS-CoV-2 infection, it has not been considered relevant in the vast majority of reported nosocomial outbre...
[Clinical characteristics and risk factors for mortality on admission in patients with heart failure hospitalized due to COVID-19 in Spain] [0.03%]
西班牙因COVID-19住院的心衰患者的临床特征及入院时的死亡风险因素分析
P Llàcer Iborra,J Núñez Villota
P Llàcer Iborra
[Acute poisoning among patients attended to in an emergency department: From the pre-pandemic period to the new normality] [0.03%]
急性中毒急诊患者从疫情前到新常态时期的特征变化分析
A F Caballero-Bermejo,J Ortega-Pérez,G Frontera-Juan et al.
A F Caballero-Bermejo et al.
Background: The COVID-19 pandemic has caused global changes that affect the daily life of the world's population, with a direct impact on individuals' physical and mental health as well as on their social and recreational...
[The evolution of SARS-CoV-2 variants and their clinical and healthcare implications] [0.03%]
[SARS-CoV-2变异株的演变及其临床和公共卫生意义]
J M Eiros,M Hernández
J M Eiros
[Systemic capillary leak syndrome after SARS-CoV-2 infection and after COVID-19 vaccination: A scoping review in relation to a clinical case] [0.03%]
[SARS-CoV-2感染和COVID-19疫苗接种后的全身性毛细血管渗漏综合征：与临床病例相关的系统综述]
M Buj,G Morales-Varas,A Pedrosa-Guerrero et al.
M Buj et al.
[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure] [0.03%]
合并心力衰竭的COVID-19患者的糖皮质激素治疗
C S Kow,D S Ramachandram,S S Hasan
C S Kow
[Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence] [0.03%]
《患有COVID-19并发心力衰竭患者的糖皮质激素治疗》的答复
A Salinas-Botrán,L M Pérez-Belmonte,M Méndez-Bailón;en representación del grupo SEMI-COVID- Network
A Salinas-Botrán
A López-Sampalo,M R Bernal-López,R Gómez-Huelgas
A López-Sampalo
As the coronavirus-2019 disease (COVID-19) pandemic, caused by the infection with severe acute respiratory syndrome (SARS-CoV-2) coronavirus type 2, has progressed, persistent COVID-19 syndrome is an increasingly recognized problem on which...